Entropin Inc – ‘8-K’ for 8/20/99

On:  Friday, 8/20/99   ·   For:  8/20/99   ·   Accession #:  1017951-99-128   ·   File #:  33-23693

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         August 20, 1999 Form 8-K                               2     10K 
 2: EX-10.15    Agreement With Therapeutic Management                 27     76K 

8-K   —   August 20, 1999 Form 8-K
Document Table of Contents

8-K
1st Page of 2
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION          

Washington, D.C.  20549         

FORM 8-K          

CURRENT REPORT          

Pursuant to Section 13 or 15(d) of          
the Securities Exchange Act of 1934         

AUGUST 20, 1999         
-----------------         
(Date of Report)          

ENTROPIN, INC.          
--------------------------------------------------------          
(Exact Name of Registrant as specified in its charter)          

COLORADO                33-23693            84-1090424        
----------------------------    -----------      -------------------            
(State or other jurisdiction    (Commission      (IRS Employer                  
of incorporation)         File Number)     Identification No.)      

21550 OXNARD STREET, SUITE 810, WOODLAND HILLS, CA 91367          
---------------------------------------------------------------------         
(Address of principal executive offices including zip code)         

(818) 340-2323          
--------------------------------------------------          
(Registrant's telephone number including area code)         

N/A         
------------------------------------------------------------          
(Former name or former address, if changed since last report)         

8-K
Last Page of 2
TOC
1st
Previous
Next
↓Bottom
Just 2nd
ITEM 5.  OTHER EVENTS.                                                          
---------------------                                                           

On August 16, 1999, the Registrant entered into an agreement with     
Therapeutic Management, an Ohio corporation ("TM").  TM will provide the        
Registrant comprehensive clinical trial management services to manage and       
monitor all aspects of the Phase III clinical studies of its drug,              
Esterom(R).  TM has developed a clinical trial management system to ensure      
quality management, making certain that all aspects of the clinical trials      
are carefully supervised.   TM is an experienced clinical research              
organization providing a complete package of clinical research services to      
the healthcare industry.                                                        

The Registrant is a pharmaceutical development company whose first    
product, Esterom(R), is about to begin Phase III clinical trials. A             
successful Phase II clinical trial was completed with results indicating        
Esterom has a quick onset of action, no observed toxicity or adverse            
effects, and high efficacy in the treatment of acute lower back sprain and      
acute painful shoulder.                                                         

ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS     
-------------------------------------------------------------------------       

(c)  The following exhibits are filed with this report:               

     Exhibit 10.15  Agreement dated August 16, 1999 by and between the
        Registrant and Therapeutic Management.

SIGNATURES          
----------          

Pursuant to the requirements of the Securities Exchange Act of 1934,  
the Registrant has duly caused this Report to be signed on its behalf by        
the undersigned, thereunto duly authorized.                                     

Date: August 20, 1999              ENTROPIN, INC.                               

By /s/ DONALD HUNTER
                  ----------------------------------
       Donald Hunter
                 Chief Executive Officer

-2-       

Dates Referenced Herein

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on / For Period End:		8/20/99		1		2			None on these Dates
		8/16/99		2
									List all Filings